Clinical Trials Browser

Active not recruiting × OTHER × Neoplasms by Histologic Type × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT04124198 2025-12-31

QoLATI

Phase NA Active not recruiting

138 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT02663297 2025-05-15

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Phase 1 Active not recruiting

18 enrolled 10 charts

Lymphoid

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

56 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Clinical Trials

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

QoLATI

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer